Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2018
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2018
SUMMARY
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 28 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter.
It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 3, 10 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Metabolic Disorders, Central Nervous System and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Endometriosis, Hormone Sensitive Breast Cancer, Osteoporosis, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Fallopian Tube Cancer, Lung Cancer, Male Hypogonadism, Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Ovarian Cancer, Peritoneal Cancer, Prostate Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
Furthermore, this report also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 28 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter.
It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 3, 10 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Metabolic Disorders, Central Nervous System and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Endometriosis, Hormone Sensitive Breast Cancer, Osteoporosis, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Fallopian Tube Cancer, Lung Cancer, Male Hypogonadism, Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Ovarian Cancer, Peritoneal Cancer, Prostate Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
Furthermore, this report also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
H3 Biomedicine Inc
Huons Global Co Ltd
Novartis AG
Nuevolution AB
Shenogen Pharma Group Ltd
ViroMed Co Ltd
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles
(bazedoxifene acetate + cholecalciferol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + GnRH Agonist + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-378 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-372 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERX-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B5942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6545 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-1153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-8023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTC-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZB-716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones
Featured News & Press Releases
Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models
Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Mar 21, 2018: UIC breast cancer drug in first human clinical trial
Dec 20, 2017: Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program
Dec 11, 2017: AstraZeneca’s Faslodex Rejects For Use Within NHS Scotland
Dec 08, 2017: Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium
Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
Dec 06, 2017: H3 Biomedicine Presents Preclinical Data on Novel ERa Antagonist at San Antonio Breast Cancer Symposium
Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib
Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer
Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
Aug 30, 2017: UT Health San Antonio researchers developing drug for recurring ER-positive breast cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
H3 Biomedicine Inc
Huons Global Co Ltd
Novartis AG
Nuevolution AB
Shenogen Pharma Group Ltd
ViroMed Co Ltd
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles
(bazedoxifene acetate + cholecalciferol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + GnRH Agonist + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-378 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-372 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERX-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B5942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6545 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-1153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-8023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTC-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZB-716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones
Featured News & Press Releases
Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models
Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Mar 21, 2018: UIC breast cancer drug in first human clinical trial
Dec 20, 2017: Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program
Dec 11, 2017: AstraZeneca’s Faslodex Rejects For Use Within NHS Scotland
Dec 08, 2017: Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium
Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
Dec 06, 2017: H3 Biomedicine Presents Preclinical Data on Novel ERa Antagonist at San Antonio Breast Cancer Symposium
Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib
Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer
Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
Aug 30, 2017: UT Health San Antonio researchers developing drug for recurring ER-positive breast cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Arvinas Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Atossa Genetics Inc, H2 2018
Pipeline by Avivia BV, H2 2018
Pipeline by Eagle Pharmaceuticals Inc, H2 2018
Pipeline by Endece LLC, H2 2018
Pipeline by EndoCeutics Inc, H2 2018
Pipeline by H3 Biomedicine Inc, H2 2018
Pipeline by Huons Global Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Nuevolution AB, H2 2018
Pipeline by Shenogen Pharma Group Ltd, H2 2018
Pipeline by ViroMed Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Arvinas Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Atossa Genetics Inc, H2 2018
Pipeline by Avivia BV, H2 2018
Pipeline by Eagle Pharmaceuticals Inc, H2 2018
Pipeline by Endece LLC, H2 2018
Pipeline by EndoCeutics Inc, H2 2018
Pipeline by H3 Biomedicine Inc, H2 2018
Pipeline by Huons Global Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Nuevolution AB, H2 2018
Pipeline by Shenogen Pharma Group Ltd, H2 2018
Pipeline by ViroMed Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
H3 Biomedicine Inc
Huons Global Co Ltd
Novartis AG
Nuevolution AB
Shenogen Pharma Group Ltd
ViroMed Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
H3 Biomedicine Inc
Huons Global Co Ltd
Novartis AG
Nuevolution AB
Shenogen Pharma Group Ltd
ViroMed Co Ltd
